Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 5/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | BPTF | Q12830 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 4/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4496899 | 0.83 | HRH3 (0.44) | DRD3KCNH2HRH3PARP1 | |
| SCHEMBL3973870 | 0.79 | HRH3 (0.41) | HRH3PARP1ALDH1A1KDM4EMAPT | |
| SCHEMBL22171249 | 0.78 | MAPT (0.51) | HRH3ALDH1A1KDM4EMAPTPKM | |
| SCHEMBL3974009 | 0.77 | DDB1 (0.46) | DRD3KCNH2SLC6A2DRD2CACNA2D1 | |
| Hydrochloric Acid SCHEMBL22165259 | 0.77 | MAPT (0.50) | HRH3ALDH1A1KDM4EMAPTPKM | |
| SCHEMBL23176630 | 0.76 | LMNA (0.44) | DRD3KCNH2HRH3DRD2ALDH1A1 | |
| SCHEMBL13256438 | 0.74 | NPC1 (0.50) | DRD3KCNH2HRH3DRD2PARP1 | |
| SCHEMBL4079481 | 0.73 | SIRT6 (0.44) | KCNH2ALDH1A1KDM4EMAPTPKM | |
| SCHEMBL17055336 | 0.73 | HRH3 (0.39) | DRD3KCNH2HRH3PARP1ALDH1A1 | |
| SCHEMBL3551615 | 0.73 | ALDH1A1 (0.50) | ALDH1A1KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601752-B2 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20070112001-A1 | Pyrrolidine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112001-A1 | Pyrrolidine derivatives | F12, F2, F11 | DRD3 985/4885KCNH2 1383/4885HRH3 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.